Progestin in hormonal replacement therapy

Włodzimierz Baranowski

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

1/2003
vol. 2

Send email

Copy url:

abstract:

Progestin in hormonal replacement therapy

Włodzimierz Baranowski

(Prz Menopauz 2003, 1: 6–13)

Online publish date: 2003/03/28

View full text Get citation

Estrogen replacement may reduce the risk of several diseases in postmenopausal women, but progestins may attenuate these benefits. While the benefits of progestins use in hormonal replacement therapy are well recognized as far as endometrial protection is concerned, their risks and drawbacks have generated controversial opinion. Several risk are attributed to progestins as a class-effect; however, the progestogens used in hormonal replacement therapy have varying pharmacological properties and do not induce the same side effects. Newly synthesized progestins (19-nor derivative) do not bind to the androgen receptor and do not exert androgenic side effect. Selection molecules devoing of estrogenic, androgenic or glucocorticoid effect should allow a larger use of the progestins in HRT without any major drawback.

keywords:

Progestin in hormonal replacement therapy

Włodzimierz Baranowski

menopause, hormonal replacement therapy, progestins